Author name: Sarah McCall

HHS Action Improves Healthcare Accessibility and Strengthens Protections against Disability Discrimination in Healthcare

The U.S. Department of Health and Human Services (HHS) today finalized a rule to increase healthcare accessibility and strengthen federal protections against healthcare discrimination based on disability. The rule was published in the May 9, 2024 Federal Register. Cure SMA participated in the Washington, DC event where HHS announced the rule, which is the first […]

HHS Action Improves Healthcare Accessibility and Strengthens Protections against Disability Discrimination in Healthcare Read More »

Genentech Releases SMA Community Letter Recapping Spring Activities

On May 3, 2024, Genentech released an update to the SMA community related to Evrysdi® (risdiplam) and Genentech’s activities in service of the SMA community. Read the full community statement here. “Many thanks to the entire SMA community who continue to inspire the broad work that we are doing from research to innovative programming. As

Genentech Releases SMA Community Letter Recapping Spring Activities Read More »

Accessible Air Travel Update – Next Steps

This week, Cure SMA urged the U.S. Department of Transportation (DOT) to strengthen and quickly implement its proposed rule on ensuring safe accommodations for air travelers with spinal muscular atrophy (SMA) and other disabilities who use wheelchairs. In the 9-page letter addressed to Secretary Pete Buttigieg, Cure SMA highlighted critical issues faced by individuals with

Accessible Air Travel Update – Next Steps Read More »

Cure SMA Launches New Resources to Enhance Clinical Trial Access

Cure SMA is pleased to announce the release of new resources to support our community’s ability to navigate the evolving landscape of SMA clinical trials. These resources are intended to build knowledge in clinical trial procedures and preparation, to enhance awareness regarding actively recruiting clinical trials and sites, and to empower our community in their

Cure SMA Launches New Resources to Enhance Clinical Trial Access Read More »

Cure SMA Announces Expanded Phase 9 of SMA Industry Collaboration 

Cure SMA is pleased to announce the launch of an expanded Phase 9 of our SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, SMA Europe, Cure SMA, and other nonprofit organizations to share information, ideas, and data to benefit the broader SMA community. Through the Industry Collaboration,

Cure SMA Announces Expanded Phase 9 of SMA Industry Collaboration  Read More »

Biogen Releases SMA Community Letter

On April 19, 2024, Biogen released an update to the SMA community sharing recent data presentations from Spring conferences and latest updates from their SPINRAZA® (nusinersen) clinical development program. Read the full community statement here. “We aspire to address the unmet needs of the SMA community and are grateful to individuals throughout the community for

Biogen Releases SMA Community Letter Read More »

Participate in the Annual Cure SMA Community Update Survey – Open Now!

For the past seven years, the Cure SMA Community Update Survey has collected data and information on the SMA community’s experiences and daily challenges. Every single individual with SMA and their families bring a unique perspective that, collectively, help us adapt to the changing landscape of SMA. Data from the survey also informs Cure SMA’s

Participate in the Annual Cure SMA Community Update Survey – Open Now! Read More »

Cure SMA Awards $150,000 Grant to Lyndsay Murray,PhD, at the University of Edinburgh in Scotland

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA biology. Our Scientific Advisory Board then ranks the submitted proposals on both their scientific merit and relevance to Cure SMA’s research priorities. Funding is awarded to the highest ranked projects.

Cure SMA Awards $150,000 Grant to Lyndsay Murray,PhD, at the University of Edinburgh in Scotland Read More »

Government Funding Bill Supports New SMA Research to Address Unmet Needs

Cure SMA’s year-long advocacy campaign to educate Congress and the Administration about the unmet needs of individuals with spinal muscular atrophy (SMA) has concluded with a major legislative victory. This weekend, the President signed into law a government funding bill that included a provision in support of new SMA research at the National Institutes of

Government Funding Bill Supports New SMA Research to Address Unmet Needs Read More »

Cure SMA Awards $114,000 Grant to Michael Tellier, PhD, at the University of Leicester in the United Kingdom

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA biology. Our Scientific Advisory Board then ranks the submitted proposals on both their scientific merit and relevance to Cure SMA’s research priorities. Funding is awarded to the highest ranked projects.

Cure SMA Awards $114,000 Grant to Michael Tellier, PhD, at the University of Leicester in the United Kingdom Read More »

Scroll to Top